Fulgent Genetics, Inc. FLGT Therapeutic Development — Finite Lived Intangible Assets Gross
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Fulgent Genetics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsGross.
The official record: Fulgent Genetics, Inc.’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →
Ask your AI about Fulgent Genetics, Inc.'s therapeutic development — finite lived intangible assets gross.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Fulgent Genetics, Inc.'s therapeutic development — finite lived intangible assets gross?
- Fulgent Genetics, Inc. (FLGT) reported therapeutic development — finite lived intangible assets gross of $2.3M in Q1 2026.
- What does therapeutic development — finite lived intangible assets gross mean?
- Represents the total historical cost of identifiable intangible assets with finite useful lives, such as patents or licenses, held by the therapeutic development segment. This metric highlights the scale of the segment's proprietary technology and legal protections before accounting for wear or obsolescence.